Mice expressing SV40 T-Antigen in liver under control of the phosphoenolpyruvate carboxykinase promoter were generated. By altering the carbohydrate content of the diet, TAg expression, the rate of hepatocyte proliferation and apoptosis, and hence hepatocarcinogenesis, could be regulated. Carbohydrate-mediated suppression of TAg resulted in slow hepatic growth that progressed to focal hepatocellular carcinoma (HCC) after a long latency period. In contrast, induction of TAg by feeding mice a low carbohydrate diet resulted in massive hepatomegaly that progressed rapidly to diffuse multifocal HCC. Hepatic TAg expression could be efficiently repressed by switching mice from the low to the high-carbohydrate diet, which if instigated prior to the development of HCC, resulted in rapid regression through a p53-independent reduction in hepatocyte proliferation and an increase in hepatocyte apoptosis. Although liver growth was accompanied by compensatory hepatocyte apoptosis, an apoptotic deficit developed following chronic exposure to high levels of TAg. This was associated with Akt phosphorylation and increased expression of the antiapoptotic molecules bfl-1/A1, TIAP, and A20. Mice were resistant to Fas-induced hepatocellular apoptosis due to severely impaired caspase activation and failed activation of the mitochondrial amplification loop. This model will be useful to investigate oncogene-mediated disruption of the cell cycle and apoptosis, and to determine which processes constitute fixed, or reversible aspects of the tumorigenic process. Oncogene (2003 Oncogene ( ) 22, 2515 Oncogene ( -2530 Oncogene ( . doi:10.1038 Keywords: T-Antigen; apoptosis; Fas; caspase; Akt; hepatocytes Hepatic homeostasis is maintained by balancing the rate of programmed cell death or apoptosis with the rate of hepatocyte proliferation, processes that operate to remove and replace damaged or senescent hepatocytes. While coordination of both processes is necessary to maintain optimal hepatic function and ensure constancy of hepatic mass in relation to overall body size, chronic dysregulation of either can lead to fulminant hepatic failure or predispose to hepatic hyperplasia and hepatocellular carcinoma. Although hepatocytes exit the cell cycle upon differentiation resulting in establishment of virtual quiescence within the normal liver, remarkable plasticity is demonstrated when liver mass expands or diminishes. For example, hepatocytes retain the ability to rapidly re-enter the cell cycle and proliferate in response to injury, or loss of hepatic mass. This involves the coordination of diverse processes including induction of immediate early genes, stimulation of the cell-cycle machinery and activation of genes involved in remodeling hepatic architecture and restoring hepatic function (Fausto, 2000) . Conversely, hepatocytes are capable of engaging the cell death machinery in response to an unscheduled expansion of hepatic mass (Kanzler and Galle, 2000) . Apoptosis can also be induced in resting liver via ligation of death receptors belonging to the tumor necrosis factor receptor (TNFR) superfamily via a pathway involving assembly of a death-induced signaling complex (DISC), activation of caspases, release of cytochrome c and the cleavage of a large number of cellular substrates resulting in dismantling of the cellular machinery and death (Sartorius et al., 2001) .
Disruption of the delicate balance between cell proliferation and cell death is considered one of the fundamental hallmarks of solid tumor development (Hanahan and Weinberg, 2000) . Malignant transformation is highly associated not only with increased proliferation but also with the acquisition of apoptotic resistance. Considerable attention is thus focused on defining the apoptotic potential of cells as they proceed to malignancy. It is also clear that regulation of the cellcycle machinery and the cell death machinery is highly coordinated (Guo and Hay, 1999) , possibly through the action of 'molecular couplers' (Abrams, 2002) . Candidates for such hypothetical couplers include the Rb/E2F, ARF/MDM2/p53 complexes (Sherr and McCormick, 2002 ) and the PI3K/Akt/PTEN signal transduction module (Vivanco and Sawyers, 2002) , all of which are critically involved in mediating cell-cycle progression and survival/death decisions. That these pathways are commonly targeted by oncogenes indicates that uncoupling of proliferation and apoptosis is necessary, although not necessarily sufficient for transformation.
An oncogene known to functionally impact all three of the above hypothetical couplers is the viral transforming protein SV40 T-Antigen (TAg). By binding to p53 and pRb, TAg inactivates many of the known activities of both tumor suppressors (Ali and DeCaprio, 2001; Pipas and Levine, 2001) , resulting in increased cell proliferation and modification of apoptotic sensitivity. However, inactivation of p53 and pRB is insufficient for oncogenic transformation (Hahn et al., 2002) , suggesting the existence of additional TAg functions that perturb cellular homeostasis. One such ancillary function appears to be TAg's activation of Akt/PKB (Yu and Alwine, 2002) , a serine-threonine kinase that acts downstream of PI3K in a pathway that regulates metabolism, cell growth, proliferation and survival (Datta et al., 1999; Vivanco and Sawyers, 2002) . Although many of the mechanisms involved in mediating TAg's stimulation of both the cell-cycle and the transcriptional machinery have been elucidated (Moens et al., 1997; Saenz-Robles et al., 2001) , its modulation of apoptosis is less clear. TAg can either enhance (Tzeng et al., 1998; Kohlhoff et al., 2000; Cole and Tevethia, 2002) or inhibit (Rouquet et al., 1995; Conzen et al., 1997; Tsai et al., 2000) apoptosis, indicating that its ability to modify apoptotic sensitivity is complex and may depend on the initiating death stimulus, cellular context and the apoptotic pathway(s) utilized by specific cell types.
Here, we describe a line of transgenic mice with hepatic expression of the viral transforming proteins SV40 T-Antigen (TAg) and t-antigen (tag) (herein referred to as TAg) directed to hepatocytes by the 5 0 regulatory sequences of the rat phosphoenolpyruvate carboxykinase (PEPCK) gene. These sequences have been used extensively to direct expression of various structural genes to the liver of transgenic mice (McGrane et al., 1990; Short et al., 1992; Eisenberger et al., 1992; Clouthier et al., 1997) . Hepatic PEPCK is the rate-limiting enzyme in gluconeogenesis, and is most highly expressed in periportal hepatocytes with a decreasing gradient of expression across the lobule (Zimmer and Magnuson, 1990) . PEPCK transcription is positively regulated by glucocorticoids, cAMP, retinoic acid, thyroid hormone and prolactin, and negatively regulated by insulin and diacylglycerol (Hanson and Reshef, 1997) . The negative regulatory effect of insulin on PEPCK transcription is dominant and robust (Pilkis and Granner, 1992) , and has been used to modulate the transcription of PEPCK-driven hepatic transgenes by altering the carbohydrate content of the diet (Short et al., 1992; Clouthier et al., 1997) . By feeding PEPCK-TAg transgenic mice specific diets, the rate and magnitude of TAg-induced hepatocyte proliferation and progression to HCC could be controlled. In livers of mice fed a high carbohydrate diet, TAg expression was repressed to extremely low levels, resulting in livers that grew slowly and progressed to HCC after a long latency period. In contrast, TAg expression was induced to high levels in mice fed a low carbohydrate diet, a regimen that resulted in rapid liver growth that progressed to HCC in 7-8 weeks. Importantly, TAg could be rapidly and efficiently repressed by switching mice from a low, to a high carbohydrate diet, a regimen that resulted in almost complete reversal of hepatic hyperplasia if initiated prior to emergence of a fully transformed cellular phenotype.
Here, we present a detailed characterization of this model, and show that the ratio of hepatocyte proliferation/death correlates precisely with the net increase or decrease in liver mass. We demonstrate that hepatocytes are exquisitely sensitive to TAg and predominantly undergo hypertrophy in response to very low levels of TAg, and proliferation in response to high levels of TAg. Suppression of TAg following a sustained, but limited period of expression results in complete inversion of the proliferation/death ratio and hepatic regression. TAg-dependent hepatocyte proliferation is accompanied by hepatocyte apoptosis. However, an apoptotic deficit prevails with increasing TAg expression and duration of TAg exposure. This deficit is associated with the induction of several antiapoptotic molecules, phosphorylation of Akt and inhibition of Fas-induced hepatocyte apoptosis owing to failed activation of both the extrinsic and intrinsic apoptotic pathways. We also demonstrate that both TAg-induced hepatocyte proliferation and death occur by p53-independent mechanisms. These mice constitute a valuable model to investigate the mechanisms by which TAg uncouples cell-cycle progression and apoptosis to drive oncogenic progression.
Materials and methods

Antibodies and cDNA probes
Primary antibodies recognizing full-length or cleaved caspases purchased from Cell Signaling (Beverly, MA, USA) were rabbit polyclonal anti-caspase 9 (# 9504) that recognizes fulllength (49 kDa) and cleaved (39 and 37 kDa) caspase 9, rabbit polyclonal anticaspase 3 (# 9661) that recognizes only the cleaved p19/20 and p17 forms of caspase 3, rabbit polyclonal anticaspase 6 (# 9762) that recognizes full-length (35 kDa) and cleaved (15 kDa) caspase 6, rabbit polyclonal anticaspase 7 (# 9492) that recognizes full-length (35 kDa) and cleaved (20 and 17 kDa) caspase 7, rabbit polyclonal anticaspase 10 (# 9752) that recognizes 64 kDa procaspase 10 and its cleaved forms. Rabbit polyclonal antibodies recognizing total Akt (# 9272) and phospho (Ser473)-Akt (# 9271) were purchased from Cell Signalling. The rabbit polyclonal anticaspase 8 antibody (AAP-118) recognizing full-length (56 kDa) and cleaved (44/42kD, 25 kD and 14 kDa) caspase 8 was purchased from Stressgen (Victoria, BC, Canada). The PAb101 mouse monoclonal TAg-specific antibody (554149) recognizing only large T-Antigen was purchased from BD Pharmingen (Piscataway, NJ, USA), and the rabbit polyclonal anti-bid antibody, recognizing full-length and cleaved bid, was provided by Dr X Wang (University of Texas Southwestern Medical School, Dallas, TX, USA). The goat-polyclonal anti-ranspecific antibody (sc-1156) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary antibodies used were donkey anti-rabbit-HRP (NA 934, Amersham Biosciences, Piscataway, NJ, USA), donkey anti-mouse HRP (715-035-150) and rabbit anti-goat HRP (305-036-045) (Jackson Immuno-Research, West Grove, PA, USA). The hamster monoclonal Fas agonist antibody (Jo-2 clone; NA/LE) 554254) was purchased from BD Pharmingen. The cDNA probe for murine A20 was provided by Dr A Ma (University of Chicago, Chicago, IL, USA) and the probe for TIAP was provided by Dr T Tokuhisa (Chiba University School of Medicine, Chiba, Japan).
Transgene construction and production of transgenic mice
To generate the PEPCK-SV40 T/t-antigen transgene (TAg), the entire SV40 early region encoding both large T-Antigen and small t-antigen were isolated from plasmid 1941B#10 (a gift of Richard Palmiter, University of Washington) and fused to 2088 bp of the rat PEPCK 5 0 flanking DNA and the first 69 bp of exon 1 (Beale et al., 1985) . The 4.6 kb transgene was microinjected into fertilized (C57BI/6 Â SJL) F2 hybrid mouse eggs as previously described (Clouthier et al., 1997) and five transgenic mice were produced. These five founder mice were subjected to partial hepatectomy and all five produced both large TAg and small tag transcripts (data not shown). Four of the mice were bred to B6SJLF1 mice and a single line (109-9) containing eight copies of the transgene was established. Genotyping of progeny was done by either dot blot analysis or by PCR using the forward primer 5 0 AGTAAAATATGCT-CATCAACC 3 0 and the reverse primer 5 0 CCTTT-GTGGTGTAAATAGCAA 3 0 , corresponding to nucleotides 4949-4969 and 4322-4342 of the SV40 genome that amplified a DNA product of 647 bp. Unless otherwise specified, hemizygous male transgenic mice and wild-type littermate controls were used for all of the described experiments.
Animal treatments
Transgenic mice used for characterizing the tissue specificity of TAg expression were fed the Teklad 4% Mouse/Rat Diet No. 7001 from Harlan Teklad Premier Laboratory Diets (Madison, WI, USA). The regulation of hepatic TAg expression was accomplished by feeding mice isocaloric diets consisting of either 65% protein-10% carbohydrate-10% fat (protein diet, # 8091), 70% carbohydrate-10% protein-8% fat (carbohydrate diet, # 22471) or a 90% carbohydrate-0% protein-8% fat (90% carbohydrate diet) (Purina Mills, Richmond, IN, USA). All transgenic and control animals were derived from pregnant females maintained on the carbohydrate diet during the entire pregnancy and neonatal period. At weaning (day 21), transgenic and wild-type mice were fed either the carbohydrate diet for colony maintenance, or fed the experimental diets described for specific experiments ad libitum. Mice were housed in conventional Plexiglass cages and maintained under a controlled environment (temperature, 20-251C; humidity, 40-60% and photoperiod, 14 h light (07:00-21:00/ 24 h)).
Generation and genotyping of TAg transgenic p53 null mice
To place the TAg transgenic locus onto the p53 null background, TAg transgenic males were bred with p53 null females (Jackson Laboratory, Bar Harbor, ME, USA). Transgenic p537; TAg + males were bred to p53 null females and pregnant females were maintained on the carbohydrate diet during pregnancy and the neonatal period. PCR genotyping for p53 was done according to the protocol recommended by the Jackson Laboratory Induced Mutant Resource.
Liver weight and DNA quantitation
For liver weight determination, animals were killed by CO 2 inhalation, weighed, and the entire liver removed, blotted dry and weighed. Liver mass was expressed as a percentage of total body weight. For DNA content determination, B100 mg of liver was removed, weighed and incubated in 4 ml of SNET buffer (1% SDS, 400 mm NaCl, 5 mm EDTA, 20 mm Tris, pH 8.0) containing proteinase K (0.2 mg/ml). The DNA content of the digested samples was measured by fluorimetry as previously described (Clouthier et al., 1997) .
RNA analysis by Northern blot hybridization
Total cellular RNA was extracted from tissues using either the guanidinium isothiocyanate-cesium chloride procedure or RNA STAT-60 reagent (Tel-Test 'B', Friendswood, TX, USA) and Northern blotting was conducted as previously described (Clouthier et al., 1997) . SV40-specific transcripts were detected using a random-oligonucleotide primed 32 P-labeled 1.56 kb XhoII fragment isolated from plasmid 1941B#10. Equality of RNA loading was assessed by hybridization of filters with a 32 P-end-labeled oligonucleotide probe for rat 18S ribosomal RNA.
RNase protection assay
Protection assays were carried out using the Riboquant MultiProbe RNase Protection Assay BD/Pharmingen (San Diego, CA, USA). Aliquots of total pooled RNA (10 mg) were subjected to solution hybridization with the 32 P-labeled RNA multiprobe template set mAPO-2 for mouse bcl-2 family members, and protected fragments were separated on 8 m urea/ 6% polyacrylamide gels. Gels were dried and exposed to XAR-5 film (Eastman Kodak Co., Rochester, NY, USA) with intensifying screens at À701C. Radioactivity was quantified by exposure of the dried gel to a PhosphorImager radioanalytic imaging instrument (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The level of GAPDH mRNA in each sample was used to normalize signals obtained for all test mRNAs. Assays were repeated three times.
Histology
Tissues were fixed in 10% neutral buffered formalin for 4 to 12 h and stored in 70% ethanol. Specimens were embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin.
Measurement of cell proliferation and apoptosis
Determination of cell proliferation and apoptosis was conducted as previously described (Clouthier et al., 1997) . For quantitation of the number of BrdU-or TUNEL-positive hepatocytes, at least 30-fields per liver section were counted at Â 600 magnification. Liver sections of at least three mice of the representative genotypes on the different dietary regimens were evaluated.
Induction of Jo-2-induced hepatocellular apoptosis.
The Fas agonist antibody Jo-2 or vehicle (saline) was administered to mice via a single intrajugular injection (0.28 mg/g body weight). Mice were killed and livers harvested 5 h post-injection.
Preparation of liver proteins
Total liver lysates were prepared as described (Kerouz et al., 1997) . Cytosolic (S-100) and mitochondrial liver proteins were prepared as described (Yin et al., 1999) , by harvesting the liver after removing the gallbladder, and washing in six volumes of ice-cold buffer A (200 mm mannitol, 70 mm sucrose 0.5 mm EGTA, 5 mm HEPES, 0.1% defatted bovine serum albumin (BSA), 1 mg/ml leupeptin, 1 mg/ml pepstatin, pH 7.2). The liver was chopped into small pieces and transferred to fresh buffer A and subjected to four strokes of a Wheaton Dounce homogenizer (Teflon pestle) and centrifuged at 600 g for 10 min at 41C. Heavy membranes and mitrochondria were pelleted by centrifugation of the supernatant at 8000 g for 10 min at 41C, washed once in buffer A and recentrifuged at 8000 g. The mitochondrial pellet was resuspended in 1 ml buffer A for subsequent immunoblot analysis. The supernatant obtained from the 8000 g centrifugation was centrifuged at 105,000 g to generate the cytosolic (S-100) fraction. Proteins generated for use in immunoblot analysis using phosphospecific antibodies were prepared in the presence of 0.5 mm EDTA, 0.5 mm EGTA, 0.1 mm sodium orthovanadate, 1 mm sodium pyrophosphate, 5 mm sodium fluoride. All proteins were aliquoted and stored at À801C. Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, II, USA) BSA as a standard.
Immunoblot analysis.
Proteins (100 mg) were separated by SDS-PAGE and transferred to Hybond nitrocellulose membranes (Amersham Pharmacia). Membranes were washed in 1 Â Tris-buffered saline (TBS) (20 mm Tris-Cl, 137 mm NaCl, pH 7.6) for 5 min at room temperature, followed by blocking twice for 1 h at room temperature in 1 Â TBS, 0.1% Tween-20, 5% w/v nonfat dry milk (TTM). Membranes were incubated with primary antibodies overnight at 41C in TTM with gentle agitation. Membranes were washed three times for 30 min at room temperature, and incubated with appropriate secondary antibody for 1-2 h at room temperature in TTM with gentle agitation. Membranes were washed in 1 Â TBS/0.1% Tween-20 for 12-16 h at room temperature, except when phosphospecific antibodies were used, in which case washing time was generally decreased to 4-8 h. Immunoreactive proteins were visualized by enhanced chemiluminescence (Western Lightning ECL, NEN Perkin-Elmer, Boston, MA, USA).
Results
TAg expression causes liver, brown fat and kidney neoplasms
To generate a line of transgenic mice with regulatable hepatic expression of SV40 T/t-antigens (TAg), we constructed a transgene encoding the entire SV40 early region driven by a 2.1 kb DNA fragment containing 2088 bp of the rat PEPCK 5 0 flanking DNA. Five founder mice were identified and four developed liver, kidney and brown fat neoplasms between 2 and 5 months of age, the tissue distribution and severity of which was founder dependent. Four founders were bred and a single line of mice was established which forms the basis of this investigation. The founder used to generate the line developed a hibernoma, had focal renal neoplasms localized to the proximal tubule epithelium and had a massively enlarged, neoplastic liver at the time of killing.
To establish the tissue specificity of transgene expression, total cellular RNA was prepared from select tissues of 4-week-old transgenic mice and from a liver tumor nodule from a 3-month-old mouse and subjected to Northern blot analysis. Both SV40 large and small tantigens (TAg) were highly expressed in the liver and the liver tumor nodule, with lower levels of TAg transcripts present in kidney, ileum and brown adipose tissue ( Figure 1) . A longer exposure of the membrane detected TAg transcripts in skeletal muscle and white adipose tissue (data not shown). This pattern of transgene expression recapitulated the hierarchy of expression found with other PEPCK-directed transgenes, and was qualitatively similar to endogenous PEPCK gene expression (Short et al., 1992; Clouthier et al., 1997) .
TAg expression is developmentally regulated and responsive to diet PEPCK gene expression in the liver is tightly regulated during development and is activated by the rapid decrease in circulating insulin that occurs immediately after birth (Girard, 1986) . To determine the temporal pattern of hepatic TAg expression and to assess the extent to which hepatic TAg expression could be suppressed in pups nursing from lactating females fed Figure 1 Tissue survey of TAg expression. Total cellular RNA was isolated from the indicated organs of three 28-day-old transgenic male mice and from a large liver tumor nodule from a 3-month-old transgenic male mouse all fed the standard rodent diet. Aliquots of RNA, 4 mg from each animal pooled and 12 mg from the tumor nodule, were subjected to Northern blot analysis as described in Materials and methods. The membrane was hybridized to a 32 P-labeled SV40 T/t-antigen-specific probe and subsequently to an 18S 32 P-labeled oligonucleotide probe. The membrane was exposed to XAR-5 film at À701C with intensifying screens for between 1 and 16 h. A 30 h exposure of the membrane hybridized to the TAg probe detected expression of TAg in skeletal muscle and white adipose tissue (not shown) a high carbohydrate diet (70% carbohydrate/10% protein), total liver RNA was isolated from P4 and P15 transgenic pups and subjected to Northern blot analysis. Hepatic TAg expression was extremely low, but detectable at P4 (data not shown) and had increased by P15 (Figure 2 , lane 2). The pattern of TAg expression is qualitatively similar to the developmental pattern of hepatic PEPCK expression (data not shown); however, the level of TAg expression is at least an order of magnitude lower than that of PEPCK expression. This difference could be attributed either to suppression of TAg expression by high carbohydrate feeding of lactating females or more likely to positional effects of transgene integration. Nevertheless, the results indicated that hepatic TAg expression could not be completely extinguished while pups were nursing.
To assess the extent to which hepatic expression of the transgene could be regulated in adults, liver RNA was isolated from transgenic mice fed either a 65% protein/ 10% carbohydrate diet (protein diet), a 10% protein/ 70% carbohydrate diet (carbohydrate diet) or a 90% carbohydrate diet for 1 or 2 weeks postweaning and analysed for TAg transcripts by Northern blot analysis ( Figure 2 ). Hepatic TAg expression was abundant after 1 week on the protein diet and increased modestly with an additional week of protein feeding. In transgenic mice fed the carbohydrate diet for 1 week, the quantity of TAg transcripts was less than half the amount present in the liver of the protein fed animals and decreased to nearly undetectable levels with an additional week of carbohydrate feeding. Increasing the carbohydrate content of the diet from 70 to 90% did not alter either the temporal pattern or magnitude of the suppression in TAg expression. Since the 70 and 90% carbohydrate diets were equally effective at suppressing hepatic TAg expression, in 70% carbohydrate diet was chosen as the TAg suppression diet for all subsequent experiments since mice had difficulty consuming the 90% carbohydrate diet because of the extreme hardness of the chow.
Modulation of TAg expression controls hepatic mass and the progression to hepatocellular carcinoma
Our characterization of the hepatic pathology in the founder and F1 and F2 transgenic progeny indicated that all transgenic mice maintained on normal chow developed a pronounced hepatocellular carcinoma between 3 and 5 months of age, consistent with the known potent oncogenic effects of SV40 T/t antigens. This observation, coupled with the finding that the transcription of this transgene could be regulated by diet, led us to ask to what extent the rate of liver growth and HCC development could be controlled by altering the carbohydrate content of the diet. Age-matched wildtype and transgenic mice were fed either the protein or carbohydrate diet for 5 or 9 weeks, and liver and body weights and gross liver morphology were assessed.
Over the time period examined, there were no significant differences in the total body weight or liver mass (4.8-5.6% of total body weight) of wild-type mice fed either diet. Transgenic mice fed the carbohydrate diet for either 5 or 9 weeks, showed a very modest, but significant increase in liver mass to 7 and 8% of body weight, respectively (data not shown). The livers of these mice appeared macroscopically normal both in color and texture and there was no overt evidence of micronodules or necrosis at either time period. Nevertheless, this small increase in hepatic mass indicated that hepatic TAg expression was not completely silenced by carbohydrate feeding. Indeed, transgenic mice chronically maintained on the carbohydrate diet did eventually succumb to hepatocellular carcinoma by approximately 20 weeks of age. At the time of killing, the livers of these mice contained, in general, two to three large nodules that accounted for most of the increased liver mass. In contrast to the carbohydrate fed mice, transgenic mice fed the protein diet for either 5 or 9 weeks exhibited a marked increase in hepatic mass to 31 and 45% of total body weight, respectively (data not shown). The livers of mice fed the protein diet for 5 weeks, while massively and uniformly enlarged, appeared macroscopically normal without any visible evidence of macro or micronodules on any lobe. In contrast, the livers of mice fed the protein diet for 9 weeks exhibited prominent disruption of the normal hepatic architecture. Abundant small and moderate sized nodules were Figure 2 Developmental and dietary regulation of TAg expression. Total cellular RNA was isolated from the livers of transgenic mice fed either the 65% protein, 70% carbohydrate or the 90% carbohydrate diet for 1 or 2 weeks beginning at 21 days of age, and from 4-and 15-day-old nursing transgenic pups with females fed the 70% carbohydrate diet. Pooled liver RNA (12 mg/lane) was subjected to Northern blot analysis (Clouthier et al., 1997) . The membrane was hybridized to a 32 P-labeled SV40 T/t-antigenspecific probe and subsequently to an 18S 32 P-labeled oligonucleotide probe. The membrane was exposed to film with intensifying screens at À801C for between 1 and 16 h Induction of hepatocyte proliferation and death SA Comerford et al dispersed randomly throughout the lobes and were commonly associated with intervening areas of necrosis that presumably resulted from local compression of the hepatic parenchyma. Thus, constitutively elevated expression of TAg in the liver results in a massive expansion of hepatic mass followed by a relatively rapid progression to hepatocellular carcinoma. In contrast, suppression of hepatic TAg expression results in a very slow increase in hepatic mass and a markedly prolonged latency of tumor formation.
To assess the hepatic morphology associated with the specific dietary regimens, wild-type and transgenic male mice were fed either the carbohydrate or protein diet for 4 weeks and the livers were removed and processed for light microscopic examination (Figure 3) . Diet had only a mild effect on the hepatic morphology of wild-type mice (Figure 3a and c) . After 4 weeks on the carbohydrate diet, the livers of transgenic mice showed remarkable heterogeneity in hepatocyte morphology and in the localization of dividing hepatocytes within the lobule (Figure 3b ). Hepatocytes within zone 3 (centro-lobular) were generally very large with either a single large nucleus or multiple small nuclei. In contrast, hepatocytes within zone 1 (periportal) were generally small and irregular in shape with a single nucleus. These hepatocytes commonly radiated approximately 2-3 layers out from the edge of the portal vein and were in very close proximity to one another giving a crowded appearance.
In contrast to the marked heterogeneous hepatocyte morphology of carbohydrate-fed transgenic mice, the livers of 4 week protein-fed transgeninc mice were remarkably uniform in structure and morphology across the lobule (Figure 3d ). Hepatocytes were generally small and densely packed across the lobule; however, a very small number of large hepatocytes resided immediately adjacent to and surrounding the central veins. The area occupied by small, densely packed hepatocytes extended across acinar zones 1 and 2 and frequently into zone 3, resulting in a considerably reduced population of large hepatocytes. Abundant mitotic figures were evident in zones 1 and 2 and hepatocyte apoptosis was apparent in both zones.
TAg withdrawal causes hepatic regression
Since chronic induction of hepatic TAg expression resulted in a greatly expanded hepatic mass, we asked to what extent suppression of hepatic TAg expression in an enlarged liver would induce hepatic regression. Agematched male transgenic mice were fed a protein diet between 1 and 5 weeks and then either killed or fed a carbohydrate diet for an additional 2-12 weeks, killed and livers removed and weighed. As expected, liver weight increased progressively during a 5-week protein feeding regimen to a mean value of 22% of total body weight ( Figure 4a ). Remarkably, after only 2 weeks of carbohydrate feeding, % liver/body values had declined by 40-66% irrespective of the duration of protein feeding. Liver size remained relatively constant during the subsequent 2 months of carbohydrate feeding but then increased dramatically, particularly in mice that had been fed the protein diet for 4 or 5 weeks. In each of these animals, the increase in hepatic mass was due, almost exclusively to the focal development and expansion of 1, 2 or 3 very large nodules most commonly involving a single hepatic lobe.
To assess the extent to which hepatic regression paralleled suppression of TAg expression, age-matched transgenic and wild-type male mice were fed the protein diet for either 2 or 5 weeks and killed, or switched to a carbohydrate diet for 2-12 weeks, killed and hepatic RNA assessed by Northern blot analysis for the abundance of TAg transcripts ( Figure 4b ). As expected, TAg expression was robust in the livers of transgenic mice on a protein diet for either 2 or 5 weeks (lane 1 and 6). Following 2 weeks of carbohydrate feeding, the level of TAg transcripts had decreased dramatically in transgenic mice from both groups and remained at very low to nearly undetectable levels until 12 weeks of The livers of the protein-fed transgenic mice exhibited marked hepatocyte hyperplasia which extended throughout the lobule and distorted the normal hepatic architecture. (e, f) Hepatocytes in wild-type mice fed on the protein diet and switched to the carbohydrate diet for 10 days exhibited prominent vacuolization. In the liver of transgenic mice there was prominent regional (zone 3) hepatocyte dropout and numerous hepatocyte apoptotic bodies and pyknotic nuclei (arrow heads) carbohydrate feeding when TAg transcripts again became detectable. The reappearance of TAg transcripts in these mice parallels an increase in hepatic mass and is most likely a reflection of the formation of focal hepatic nodules composed of dysplastic hepatocytes that have lost the capacity to respond to insulin-mediated suppression of PEPCK-driven transcription (data not shown). Thus, while suppression of TAg in an enlarged liver caused rapid hepatic regression to near normal size, complete and sustained repression of TAg expression could not be achieved and animals eventually develop HCC with distinct morphologies that depend entirely on the level and duration of TAg exposure.
To determine the extent to which TAg-induced changes in hepatic mass reflected a flux in hepatocyte cell number and/or cell size, groups of age-matched transgenic and wild-type male mice were fed either a protein diet for 2 or 5 weeks and killed or fed a protein diet for 5 weeks and then switched to a carbohydrate diet for either 1, 2 or 14 days, killed and liver weight measured and liver DNA content quantified (Table 1) . Neither weight nor the DNA content of livers of wildtype mice was affected by diet. In contrast, hepatic mass increased 2.5-and 5.6-fold in transgenic mice on the TAg-inducing (protein) diet for 2 or 5 weeks, respectively. This increase in liver mass was accompanied by a disproportionate increase in hepatic DNA content indicating that hepatomegaly was due principally to hyperplasia, a finding that was corroborated by histology ( Figure 3d ). Flow cytometry analysis of hepatocyte ploidy indicated that the population of tetraploid hepatocytes in the livers of 5-week proteinfed transgenic mice had nearly doubled relative to their wild-type littermates on the same dietary regimen (data not shown), indicating that robust TAg expression induces hepatomegaly characterized by increased number, diminished size and altered hepatocyte ploidy. Transgenic mice switched to the TAg-suppressing diet immediately following 5 weeks of TAg induction underwent a rapid decline in liver mass and showed a concomitant decrease in hepatic DNA content after as little as 24 h of TAg suppression (Table 1) . Liver mass continued to decline during the next 24 h and, following a further 2 weeks of carbohydrate feeding, the liver had regressed by 70% while hepatic DNA content had decreased by 80%. Thus suppression of TAg by Transgenic male mice, 28 days old, were fed the protein diet for either 2 or 5 weeks and then fed the carbohydrate diet for 0-12 weeks. At the designated times, total cellular RNA was isolated from a piece of the liver (three animals/ time period) and 4 mg from each animal was pooled and subjected to Northern blot analysis. The membrane was hybridized to a 32 Plabeled SV40 T/t-antigen specific probe and subsequently to an 18S 32 P-labeled oligonucleotide probe. The membrane was exposed to XAR-5 film at À701C with intensifying screens for 1-16 h Control group consisted of 12 nontransgenic animals (three each group) maintained on either one of four dietary regimens. The regimens were a protein diet for either 2 weeks (2P) or 5 weeks (5P) or a protein diet for 2 or 5 weeks followed by a carbohydrate diet for 2 or 5 weeks. The diets did not affect either the liver weight or DNA content and therefore control values were pooled. To induce TAg expression, transgenic mice were placed on either the 2P or 5P dietary regimen. To suppress TAg expression, mice that were on a 5P regimen were switched to a carbohydrate diet for either 1, 2, or 14 days (1DC, 2DC, or 14DC). b Livers were removed and weighed.
c Pieces of liver were removed, weighed and homogenized in SNET buffer with proteinase K (see Materials and methods). The DNA content was determined as described.
d
The fold change was determined in (A) and (B) by comparing the means for control versus transgenic Induction of hepatocyte proliferation and death SA Comerford et al carbohydrate feeding resulted in the rapid onset of hepatic regression that appeared to be due, in part, to a massive loss of hepatocytes.
TAg-induced perturbation of hepatic mass occurs through alterations in the balance of hepatocyte proliferation and apoptosis.
BrdU immunolocalization and TUNEL analysis were used to assess the association between the levels of hepatic TAg expression and the incidence of hepatocyte proliferation and apoptosis, respectively. Transgenic and wild-type mice were fed either a protein (4P) or carbohydrate (4C) diet for 4 weeks, or placed on a 4P regimen and switched to a carbohydrate diet for either 3 days (4P/3DC) or 10 days (4P/10DC), killed and the livers processed for histology ( Figure 5 ). The numbers of BrdU-and TUNEL-positive hepatocytes were assessed in sections of liver by quantitative morphometry and the proliferative (P) and cell-death (D) indices and ratios calculated (Table 2) .
Wild-type mice on a 4C diet regimen exhibited both an increased incidence of proliferating and dying hepatocytes compared with age-matched littermates on the 4P regimen indicating that carbohydrate feeding accelerates hepatocyte turnover (Table 2 ). In transgenic mice on a 4C regimen, B5% of hepatocytes, particularly the smaller cells located in acinar zone 1, were undergoing active DNA synthesis, while B2% of hepatocytes were undergoing apoptosis (Figure 5c, d ; Table 2 ). The result of this perturbation in hepatocyte turnover is a net 2.3-fold increase in cell number. In contrast, in transgenic mice on the 4P regimen, B13.3% of hepatocytes scattered across the lobule were proliferating, while only B3.8% of hepatocytes were dying (Figure 5e and f; Table 2 ). The result of this flux in hepatocyte turnover is a net B3.5-fold increase in cell number. Thus, while the degree of hepatocyte proliferation and death is dependent on the level of TAg expression, the magnitude of the proliferative response in mice on both diet regimens is larger than the incidence of apoptosis, and liver mass increases.
This same histological analysis was used to assess whether hepatic regression following TAg suppression occurs through alterations in either hepatocyte proliferation and/or cell death. Following 3 days of TAg suppression, there was a dramatic decrease in proliferating hepatocytes and an increase in hepatocytes undergoing apoptosis, such that the P/D ratio was o1 resulting in a net loss of liver mass (Table 2) . At 10 days following TAg suppression (Figure 5g and h), the proliferative index had dropped from 13.3 to 3.5 and the death index had risen from 3.8 to 15 (D/P ratio of 4.3, Table 2 ), resulting in a dramatic reduction in liver mass (data not shown). These results suggest that two distinct 'periods' of apoptosis are operating to limit the growth of TAg livers. The degree of cell death during the first period is relatively modest and occurs in response to TAg-induced hepatocyte proliferation (TAg-dependent), while the degree of apoptosis during the second period is robust and occurs in response to TAg suppression to effect rapid hepatic regression (TAgindependent). Confirmation that hepatocytes were dying via apoptosis was obtained by light microscopic examination of sections of liver from 4P/10DC mice (Figure 3e and f) and by oligonucleosomal DNA fragmentation analysis of regressing livers (data not shown).
Hepatic hyperplasia and regression are p53-independent The oncogenic potential of TAg resides, in part, Figure 5 Modulation of hepatocyte proliferation and death by dietary manipulation of TAg expression. Sections of liver from agematched wild-type (a, b) and transgenic (c-h) male mice fed either the carbohydrate (4C) or protein (4P) diet for 4 weeks or the protein diet for 4 weeks followed by the carbohydrate diet for 10 days (4P/10DC). (a, c, e, g) Proliferating hepatocytes were marked by bromodeoxyuridine labeling, and were detected by immunohistochemical methods using DAB (brown deposits) as the substrate (Clouthier et al., 1997) . Sections were counterstained with hematoxylin (180 X). (b, d, f, h) Apoptotic hepatocytes (FITClabeled) were detected using the TUNEL assay (Clouthier et al., 1997) . Sections were counterstained with propidium iodide (red) and viewed and photographed using a Leica DMRX microscope with a Green/Red flourescent filter that highlighted apoptotic cells as yellow (180 X). (a, b) In wild-type mice, hepatocyte proliferation and apoptosis is negligible. (c, d) In transgenic mice on the 4C regimen, hepatocyte proliferation is accompanied by hepatocyte cell death. (e, f) In transgenic mice on the 4P regimen, there is a dramatic increase in proliferating hepatocytes and a moderate increase in hepatocyte cell death. (g, h) In transgenic mice on the 4P/10C regimen, hepatocyte proliferation is severely reduced while the number of hepatocytes undergoing cell death is markedly increased. Table 2 contains quantitative analysis of the changes in hepatocyte proliferation and death by modulating hepatic TAg expression in its ability to bind and inactivate the tumor-suppressor p53, thereby preventing it from arresting cell-cyle progression and/or inducing apoptosis (Pipas and Levine, 2001 ). However, the requirement for functional p53 in controlling cell proliferation and/or cell death is highly cell-type-and context-dependent (Sionov and Haupt, 1999) and little information exists on the amount of TAg required to completely inactivate p53. Since hepatic TAg expression is very low in carbohydrate-fed mice, and high in protein-fed mice, the level of TAg may be insufficient to completely abrogate p53 function in carbohydrate-fed mice. To test the possibility that the distinct hepatic phenotypes seen in carbohydrate-and protein-fed transgenic mice may be attributable to differences in the efficiency of TAg-mediated abrogation of p53, the TAg transgene locus was bred into a p53À/À background and compound transgenic mice placed on either a 4C, 4P or 4P/10DC dietary regimen and liver phenotypes evaluated.
Loss of p53 had no effect on the TAg-induced changes in liver mass on either the 4P or 4C dietary regimens ( Figure 6 ). Furthermore, the loss of p53 did not alter either the kinetics or the magnitude of hepatic regression in transgenic mice on the 4P/10DC dietary regimen. Histological analysis of sections of liver from 4P/10DC mice confirmed that neither the hepatic proliferation index, nor the number of cells undergoing apoptosis was affected by the loss of p53 (data not shown). These results suggest that either p53 plays only a minimal role in modulating TAg-induced hepatocyte proliferation and apoptosis, or that the very low level of TAg expressed in carbohydrate-fed transgenic mice is sufficient to inactivate p53.
Robust TAg-induced hepatic growth is associated with increased expression of antiapoptotic molecules
The bcl-2-related proteins constitute a family of both pro-and antiapoptotic molecules intricately involved in the control of apoptosis (Cory and Adams, 2002) . We used RNase protection analysis to investigate if either the TAg-dependent or -independent apoptosis in transgenic mice on 4C, 4P or 4P/10DC regimens resulted from changes in expression of bcl-2 related molecules. The results of the analysis are shown in Figure 7 , quantified on Table 3 and reveal three distinct expression profiles. Expression of the antiapoptotic molecules bcl-X L and bcl-w was robust and independent of diet or phenotype. Expression of the proapoptotic molecules bak, bad and bax was moderately induced in the livers of all TAg mice and was independent of the level of TAg expressed and p53 status. Relative increases in the expression of these molecules over wild-type mice on equivalent diets ranged from 1.5 to 3.2-fold (Table 3) . Expression of bfl-1/A1, a prosurvival member of the bcl-2 family, distinguished a third expression profile. Its expression was highly induced in TAg livers (Figure 7 ) with the level of induction generally independent of the level of TAg expressed, ranging 4-27-fold when compared to appropriate wild-type littermates (Table 3) . While the level of bfl-1 transcripts in TAg livers was robust in mice on the 4C regimen, its expression in p53À/À: TAg mice was approximately twofold higher than in livers of p53+/+: TAg mice. This result suggests that the low level of TAg in hepatocytes of 4C mice is insufficient to completely inactivate p53, and that p53 deficiency may promote hepatocyte survival by enhancing bfl-1 expression in a background of low TAg expression.
Transcriptional profiling of liver RNA from wild-type and TAg mice on a 4P diet regimen (data not shown) also indicated that additional antiapoptotic molecules were induced by robust hepatic TAg expression. These included another member of the bcl-2 family, mcl-1, the cytoprotective molecule A20, and two members of the inhibitor of apoptosis (IAP) family, BRUCE/Apollon and the mouse survivin homolog, TIAP. Transcriptional induction of A20 and TIAP in the livers of 4P TAg mice was confirmed by Northern blotting (Figure 8 ). Induction of this cadre of antiapoptotic molecules suggests that robust TAg expression not only promotes hepatocyte proliferation, but also strongly favors an environment that promotes the survival of select cells within the liver.
Inhibition of Fas-induced hepatocellular apoptosis by TAg: failed activation of caspases and cleavage of bid
The increasing apoptotic deficit associated with TAgdependent liver growth, together with the induction of several prosurvival molecules, prompted us to evaluate the magnitude of, and investigate the mechanisms of resistance to death-receptor-induced apoptosis. To determine if the full complement of molecules necessary to transduce death-receptor-initiated signals was present in liver, and to assess if TAg altered their expression pattern, we performed RNase protection analysis of components of the Fas and TNFR signaling pathways including Fas, FasL, Fas2L, FLICE, FAP, FADD, TNFR1-p55, TRADD and RIP. The full complement of molecules was present and both the pattern and magnitude of expression was unaffected by TAg (data not shown). To initiate a robust apoptogenic response via activation of Fas, we employed the well-characterized in vivo model of Jo-2 induced hepatocellular apoptosis (Ogasawara et al., 1993) . The Fas-agonist Figure 7 Changes in the amount of mRNA for bcl-2 family members in the liver of wild-type and transgenic male mice on different dietary regimens as measured by RNase protection analysis. Wild-type (À) and TAg (+) transgenic male mice on either a p53 wild-type (+/+) or null (À/À) background (three mice of each genotype) were placed on the following dietary regimens: 4 weeks carbohydrate diet (4C), 4 weeks protein diet (4P) or 4 weeks protein diet followed by 10 days on the carbohydrate diet (4P/ 10DC). Aliquots of total liver RNA (10 mg) from pooled samples were subjected to RNAse protection analysis using the RiboQuant Multi-Probe RNase Protection Assay System and the mouse apoptosis-related (mAPO-2) probe set. The protected fragments were separated by gel electrophoresis, the gels dried and exposed to film for 16 h at À801C. The radioactivity in the gel was quantified and normalized to the GAPDH signal and the fold differences relative to p53 +/+: TAg negative mice on the 4-week carbohydrate diet are shown in Table 3 Values were determined by phosphorimage analysis of the protection assay shown in Figure 8 and were corrected for differences in the loading of RNA as assessed by quantitation of GAPDH. The values represent fold differences relative to p53 +/+: TAg-mice on a 4-week carbohydrate diet. b Dietary regimens are described in legend to Figure 7 . Figure 8 TAg-induced expression of antiapoptotic molecules: TIAP/survivin and A20. Total cellular RNA was isolated from the livers of three male wild-type and three transgenic mice fed the 65% protein diet for 4 weeks (4P) and subjected to Northern blot analysis as described in Materials and methods. Membranes were probed with a 32 P-labeled mouse TIAP/survivin-specific probe and an A20-specific probe and subsequently to an 18S 32 P-labeled ologonucletide probe. The membranes were exposed to film with intensfying screens at À801C for 4-48 h antibody Jo-2 (or saline vehicle) was administered to wild-type and TAg mice on a 6.5P diet regimen, and animals were killed 5 hours postinjection and assessed for their relative sensitivity to Jo-2 by evaluating the degree of hepatic destruction and activation of caspases. At autopsy, livers from TAg mice were strikingly less hemorrhagic that their Jo-2 treated wild-type littermates, an observation that was confirmed histologically by the maintenance of endothelial cell integrity and lack of hemorrhagic infiltrates in transgenic livers (Figure 9a) . Analysis of caspase cleavage in wild-type livers by immunoblotting confirmed that cleavage of caspase 8, the most distal initiator caspase in death-receptorinduced apoptosis, was complete 5 hours post Jo-2 treatment (Figure 9b ). Caspase 8 cleavage products are not shown. This result was in marked contrast to Jo-2-treated TAg livers, in which full-length caspase 8 remained virtually intact. In addition, cleavage of bid, a known substrate of caspase 8, was also inhibited in Jo-2-treated transgenic livers. This was indicated by both the absence of full-length bid (22 kDa) and the presence of the 7 kDa bid fragment in Jo-2-treated wildtype liver cytosols, and the presence of only uncleaved 22 kDa bid in TAg livers (Figure 9b) . Consistent with the failure of caspase 8 to activate bid was the severely impaired cleavage of procaspase 9 in Jo-2-treated TAg livers (Figure 9b) . On longer exposure, the p39 and p37 cleaved forms of caspase 9 were apparent following Jo-2 treatment, indicating very weak activation of the mitochondrial loop in the absence of any discernible caspase 8 or bid cleavage (Figure 9b ). This result indicates that TAg hepatocytes are partially sensitized to apoptosis via the intrinsic pathway in a caspase 8-and bid-independent manner. Expression of caspase 10, a third initiator caspase activated in response to stimulation of the Fas pathway (Kischkel et al., 2001) , was significantly reduced in TAg-expressing livers and procaspase 10 was not cleaved following Jo-2 treatment. Analysis of the downstream effector caspases 3,6 and 7 and their cleavage patterns following Jo-2 treatment revealed that while all three were robustly cleaved in wild-type livers, activation of all three was impaired to varying degrees in transgenic livers (Figure 9c ). Caspase 6 was completely cleaved in Jo-2 treated wild-type livers, and in contrast, was unaffected in TAg livers (Figure 9c) . Activation of caspase 3 and 7 was extensive in livers of Jo-2-treated wild-type mice, whereas only partial cleavage of both caspases was observed in Jo-2-treated transgenic livers (Figure 9c ). Of interest was that the p20 cleaved form of caspase 7 was clearly visible in untreated transgenic livers, and underwent additional proteolysis in response to Jo-2 stimulation. Faint caspase 3 cleavage products, particularly the p20 and p17 forms, were frequently evident in untreated transgenic livers following a period of robust TAg stimulation (data not shown) and their abundance increased following Jo-2 stimulation (Figure 9c ). These results indicate that hepatic TAg expression initiates an apoptotic response in liver through a pathway involving cleavage of caspase 3 and 7, but that over time, an apoptotic deficit arises as a consequence of TAg-mediated inhibition of caspase activation resulting in a virtually complete blockade of all downstream events required to activate mitochondrial-dependent and -independent hepatocyte apoptosis.
TAg expression induces constitutive phosphorylation of hepatic Akt
The serine/threonine kinase Akt/PKB is a key regulator of intracellular signal transduction that occupies a critical node at the intersection of multiple pathways that regulate insulin signaling, cell-cycle progression and apoptosis (Datta et al., 1999) . and has recently been shown to mediate TAg-dependent cell survival (Yu and Alwine, 2002) . To determine if either expression of Akt, or phosphorylation of key residues associated with Akt activation was increased in TAg livers, we analysed Ser473 phosphorylation of Akt in wild-type and TAg livers 7Jo-2 treatment by immunoblotting. Total Akt expression did not differ between the livers of untreated wild-type and transgenic mice (Figure 10 ). However, Akt expression was significantly reduced in livers of Jo-2-treated wild-type mice, consistent with Akt cleavage during the latter stages of apoptosis (Widmann et al., 1998) . Phosphorylation of Akt on Ser473 was essentially undetectable in livers of saline and Jo-2 treated wildtype mice (Figure 10 ). However, livers of saline and Jo-2-treated transgenic mice demonstrated constitutive phosphorylation of Ser473, which after Jo-2-treatment was modestly increased. This result is consistent with TAg-induced activation of hepatic Akt and its possible promotion of oncogenesis through delivery of an antiapoptotic signal.
Discussion
By directing expression of SV40 TAg to livers of transgenic mice using the 5 0 regulatory sequences of the rat PEPCK gene, we have developed a unique model of hepatocarcinogenesis and liver regression, in which hepatocyte proliferation and apoptosis, and hence HCC progression, can be controlled by regulating the level of TAg expression. Efficient transgene regulation was achieved by altering the carbohydrate content of the diet to influence circulating insulin levels, a regimen known to modulate hepatic PEPCK transcription. TAg expression was suppressed, although not completely silenced, in livers of mice fed a carbohydrate-rich diet, resulting in livers that grew slowly and developed HCC only after a long latency period. In contrast, TAg expression was strongly induced in mice fed a proteinrich diet, a regimen that resulted in robust liver growth, which progressed rapidly to HCC. TAg expression could also rapidly and efficiently repressed by switching mice from the protein diet to the carbohydrate diet, a regimen that resulted in liver regression through a combination of hepatocyte growth arrest and apoptosis.
Many transgenic models of TAg-induced HCC have been described using either constitutively active or more recently, inducible promoters (Merlino, 1994; Manickan et al., 2001) . While these models have been used to illustrate the potency of TAg as an oncogene, none has been used to address the consequences of inducing TAg for defined lengths of time, and subsequently silencing expression. Such a model would permit rigorous evaluation of the molecular and cellular events associated with regression following TAg silencing and, more importantly, identify the point beyond which hepatocytes no longer retain their sensitivity to growth inhibition and apoptosis following oncogene withdrawal. The line of transgenic mice expressing a regulatable TAg transgene highlighted in this report represents a novel model of oncogene-induced liver cancer that we have used to address preneoplastic liver growth and its reversibility.
Quantitative differences in total hepatic TAg expression between mice fed the different diets were reflected by marked differences in liver DNA content, hepatocyte morphology and rates of hepatocyte proliferation and apoptosis. Slow liver growth in carbohydrate-fed mice was due to a combination of hepatocyte hypertropy and Figure 10 Constitutive activation of Akt in the TAg mice. Wildtype (WT) and TAg mice were fed the 65% protein diet for 6.5 weeks and injected with either saline (À) or Jo-2 amtibody (+) and killed 5 h later. Liver cytosolic fractions were assessed for changes in the phosphorylation of Ser473 and total Akt immunoblot analysis hepatic hyperplasia, while rapid liver growth in proteinfed mice was exclusively because of hepatic hyperplasia. Significant differences were also seen with respect to tumor morphology and latency. Dietary repression of hepatic TAg expression resulted in long tumor latency and a stochastic pattern of tumor growth, often involving only a single liver lobe, while chronically high TAg expression resulted in rapid and uniform tumor growth involving all lobes. The uniformity and multiplicity of nodule development in livers of protein-fed mice was likely because of a larger number of hepatocytes expressing high levels of TAg as a consequence of increasing PEPCK expression both quantitatively and spatially within the liver lobule by suppressing circulating insulin levels (Pilkis and Granner, 1992; Short et al., 1992) .
Although TAg's association with p53 disrupts its ability to effect growth arrest and apoptosis (Pipas and Levine, 2001) , neither the kinetics of growth or regression, nor rates of hepatocyte proliferation or apoptosis in PEPCK-TAg livers were significantly altered when the transgene was introduced into a p53-deficient background. Little is known as to how much TAg is required to inactivate p53, particularly in hepatocytes in vivo, and whether the amount of TAg expressed in livers of carbohydrate-fed TAg mice was sufficient to completely inactivate p53 was not formally addressed in this study. However, bfl-1 induction appeared to be augmented in carbohydrate-fed p53À/À TAg mice indicating that the low level of TAg may be insufficient to completely abrogate p53 function. More importantly, it suggests that p53 may normally suppress bfl-1 expression in a manner analogous to its suppression of bcl-2 (Miyashita et al., 1994) , thereby altering the balance between pro-and antiapoptotic molecules to influence cell fate. Despite these results, our failure to demonstrate alterations in the kinetics of liver growth or regression in the absence of p53 in livers of mice fed any of the different diets strongly suggests that hepatocyte proliferation and death in this model are largely p53-independent. This is consistent with the known cell-typespecific effects of p53 (Sionov and Haupt, 1999) and with studies showing that it is dispensable for modulating hepatocyte proliferation and apoptosis induced by other stimuli (Bennoun et al., 1998; Bellas and Sonenshein, 1999) .
Compensatory apoptosis consistently accompanied TAg-dependent hepatocyte proliferation. Whether this represents direct activation of the apoptotic machinery by TAg or is simply a general apoptotic response to aberrant hepatocyte proliferation is unknown. There is considerable evidence for both positive and negative modulation of apoptotic sensitivity by the transforming proteins encoded by SV40 and other DNA tumor viruses (Conzen et al., 1997; Fearnhead et al., 1998; Phillips et al., 1999; Kohlhoff et al., 2000; Rodier et al., 2000; Tsai et al., 2000; Cole and Tevethia, 2002) . These proteins can sensitize cells to apoptosis mediated by both the death-receptor (extrinsic) pathway (Phillips et al., 1999) via activation of caspase 8 (Sartorius et al., 2001) , and the intrinsic pathway (Cole and Tevethia, 2002; Fearnhead et al., 1998) via an Apaf-1/cytochromec/caspase-9-dependent mechanism (Li et al., 1997; Zou et al., 1999) . Although triggering of both pathways relies on different stimuli, crosstalk between both is mediated by bid, which upon cleavage by caspase 8 translocates to the mitochondrion, and triggers activation of mitochondrial-dependent apoptosis resulting in amplification of the cascade by increasing the efficiency of caspase activation (Li et al., 1998; Luo et al., 1998) . Although the number of dying hepatocytes during compensatory apoptosis was low, our ability to detect cleavage products of caspase 3 and caspase 7 in the absence of discernible caspase 8 or bid cleavage indicates either that the initiator caspases are activated at a very low level, or that TAg renders hepatocytes sensitive to apoptosis via an unknown trigger. Indeed, the ability of TAg to sensitize cells to apoptotic stimuli including the DNA damaging agent 5-fluorouracil (Cole and Tevethia, 2002) and oxidative stress (Kohlhoff et al., 2000) has been described, and may operate via a caspase-2 dependent machanism (Lassus et al., 2002) . Further investigation into TAg's ability to sensitize cells to apoptosis is needed to determine how TAg modifies the apoptotic machinery in cells types that have differential requirements for mitochondrial-dependent amplification of the apoptogenic signal (Scaffidi et al., 1999) .
Despite the compensatory apoptosis that accompanied TAg-dependent growth, an apoptotic deficit gradually developed in the liver, the oneset of which correlated with increasing levels and duration of TAg expression. This indicated that two opposing mechanisms were operating in transgenic livers: a proapoptotic mechanism favoring compensatory hepatocyte apoptosis to counteract TAg-dependent hepatocyte proliferation, and an antiapoptotic mechanism that eventually predominated following chronic exposure to high levels of TAg. Nodules that developed late generally demonstrated significantly less, and in some cases a complete absence of apoptotic cells (data not shown), strongly supporting the hypothesis that acquired cellular resistance to apoptosis contributes to tumor progression (Hanahan and Weinberg, 2000) . This has been definitely demonstrated in elegant experiments by Pelengaris et al. (2002) in which suppression of apoptosis by overexpression of bcl-X L was sufficient to trigger rapid tumor progression in a transgenic model of c-Mycinduced b-cell tumorigenesis. These results suggest the possibility that a key factor in determining the greater oncogenic potential of TAg versus c-Myc may lie in TAgs ability to block apoptosis by transcriptionally activating cell-type-specific antiapoptotic molecules and/ or activating Akt. Alternatively, that this node was not blocked by c-Myc in b cells could reflect differences in the levels of apoptotic inhibitors or survival factors expressed, or in the pathways utilized by b-cells and hepatocytes to effect cell death.
To identify key molecular signatures of TAg-dependent tumorigenesis, we performed array analysis of gene expression in livers of PEPCK-TAg mice on different diet regimens (data not shown). From this analysis we identified several molecules that were highly induced in response to robust levels of TAg that were indicative of an 'antiapoptotic' state. These represented mRNAs for bfl-1/A1, mouse survivin (TIAP), BRUCE/Apollon, A20 and mcl-1, all of which inhibit apoptosis at distinct nodes. bfl-1/A1 is a TNF-a/NF-kB-inducible prosurvival bcl-2 homolog that suppresses TNF-a and chemotherapy-induced apoptosis (Wang et al., 1999b) by binding to bid and inhibiting the formation of proapoptotic complex at the mitochondrion (Werner et al., 2002) . As induction of bfl-1/A1 through activation of NF-kB promotes hepatocyte survival (Beg and Baltimore, 1996) , cooperativity between NF-kB and TAg would strongly favor tumor progression through enhanced hepatocyte survival and proliferation. A second antiapopototic molecule induced in TAg livers was A20, a cytoplasmic zinc-finger protein originally identified as a TNF-a -inducible gene in endothelial cells (Opipari et al., 1990) . A20 overexpression prevents TNF-a and Fas-induced apoptosis in a variety of cells types (Sarma et al., 1995; Grey et al., 1999) and protects mice against d-galactosamine/lipopolysaccharide-induced hepatocyte apoptosis (Arvelo et al., 2002) . TAg also induced the expression of the prosurvival bcl-2 homolog, mcl-1 (data not shown), a transcriptional target of activated P13K/ Akt signaling (Wang et al., 1999a,b) . Finally, two molecules frequently overexpressed in human cancer, TIAP/survivin (Kobayashi et al., 1999; Altieri, 2001) and BRUCE/Apollon (Hauser et al., 1998; Chen et al., 1999) (data not shown) belonging to the Baculovirus IAP repeat (BIR) containing family of apoptosis inhibitors (Deveraux et al., 1999) , were also induced in transgenic livers. Our finding that expression of TAg induces a cadre of structurally and functionally diverse molecules with potent antiapoptotic activity indicates that SV40 utilizes multiple straegies to counteract host responses and ensure its propagation.
TAg also induced the constitutive phosphorylation of Akt, providing another fail-safe mechanism to circumvent death. Akt is a potent antiapoptotic molecule positioned at the critically important P13K/Akt node in the overall cell signaling network that impacts tumorigenesis through its effects on cell growth, proliferation, apoptosis and motility (Datta et al., 1999; Vivanco and Sawyers, 2002) . Akt exerts antiapoptotic influence via multiple mechanisms including phosphorylation-based inactivation of proapoptotic molecules Datta et al., 1999; Cardone et al., 1998) , stimulation of NF-kBdependent transcription (Romashkova and Makarov, 1999) and inhibition of mitochondrial cytochrome c release (Kennedy et al., 1999) by coupling glucose metabolism to mitochondrial function through hexokinase (Gottlob et al., 2001) . Identification of the molecules that couple TAg to Akt activation and its potential downstream substrates should provide insight into additional mechanisms contributing to TAg-induced oncogenesis.
Expression of TAg is known to inhibit hepatocellular apoptosis induced by Jo-2; however, insight into the possible mechanisms of this blockade has not been provided (Rouquet et al., 1995) . In this study, we have confirmed that robust TAg expression in hepatocytes blocks Jo-2-induced apoptosis and have provided evidence for several mechanisms by which this inhibition may occur. Whether TAg inhibits Fas-mediated apoptosis at a single, or at multiple points in the cascade cannot be definitively determined because of the absolute dependence of hepatocytes on amplification of the death signal through bid-mediated activation of the mitochondrial pathway (Scaffidi et al., 1999; Yin et al., 1999) . Inhibition of the most apical event in the Fas pathway was evident as caspase 8 cleavage was completely blocked in Jo-2 treated TAg livers. This block would theoretically be sufficient to render TAgexpressing hepatocytes resistant to apoptosis because of the failure of caspase 8 to cleave bid and activate the mitochondrial amplification loop. Polyomavirus large T-Antigen, a relative of SV40 TAg, impairs Fas, TNF-a and taxol-induced apoptosis by interfering with DISCmediated activation of caspase 8 at the cell surface (Rodier et al., 2000) , suggesting that non-nuclear TAg functions likely contribute to transformation. However, as many of the molecules implicated in protection against apoptosis in our model inhibit apoptosis at, or close to mitochondria, it is likely that the mitochondrion represents an important blocked node in the cascade. Reduced caspase 10 expression in TAg livers is also consistent with reports showing that both reduced expression and inactivating mutations in caspase 10 are associated with malignancy (Kischkel et al., 2001; Park et al., 2002) . A reduction in the level of expression of this initiator caspase constitute another mechanism by which apoptosis is suppressed by TAg.
Further investigations into the precise mode of action of TAg at specific nodes in the apoptotic cascade are warranted to determine if induction of bfl-1/A1, mcl-1, TIAP and A20, activation of Akt and inhibition of caspase activation and bid-dependent activation of the intrinsic pathway, are independent antiapoptotic functions elicited by TAg, or whether they are functionally linked and arise as a consequence of a single lesion in the pathway. This has significance for designing strategies to force re-engagement of the stalled apoptotic machninery in neoplastic disease. As TAg and tag deregulate both common and distinct pathways (Rundell and Parakati, 2001) , it is not possible to distinguish between the individual contributions of TAg and tag to apoptotic resistance in these mice. Experiments addressing this issue have been conducted in transgenic mice expressing either tag or mutant TAgs. Expression of tag alone is sufficient to render hepatocytes resistant to Jo-2-induced apoptosis in vivo, an effect that correlated with Akt activation (Gillet et al., 2001) . However, experiments with mice expressing only wild-type TAg were not conducted, and therefore an independent role for TAg in activating Akt cannot be ruled out (Yu and Alwine, 2002) .
Dietary-mediated suppression of TAg following sustained elevated expression resulted in hepatic regression characterized by decreased hepatocyte proliferation, and increased hepatocyte death, despite the fact that several prosurvival mechanisms were operational.
Inversion of the P/D ratio following suppression of TAg demonstrated that hepatocytes were able to engage rapidly the apoptotic machinery to restore tissue homeostasis following a period of oncogene-driven proliferation. However, our ability to trigger efficient hepatic regression was inversely proportional to the duration of TAg exposure, and was most effective if instigated prior to the appearance of tumor nodules. Whether this was due to the inability to repress TAg in nodules, or because of the implementation of additional antiapoptotic mechanisms in hepatocytes within nodules was not addressed. However, the results are consistent with those of Ewald et al. (1996) in which reversal of salivary gland hyperplasia following TAg silencing occurred only if transgene expression was extinguished prior to the acquisition of polyploidy. That apoptosis was triggered so rapidly not only suggests that TAg only temporarily suppresses apoptosis, but also that prior exposure of hepatocytes to TAg renders them highly sensitive to death signals once oncogenic stimulation is suppressed. An important goal of future studies is to determine the apoptotic pathway(s) triggered by TAg withdrawal.
In summary, we have generated a useful transgenic mouse model to investigate mechanisms regulating hepatocyte proliferation and sensitivity to apoptosis during oncogenesis and regression. Identification of signature pathways and processes associated with early and late stages of TAg-induced oncogenesis should not only provide information on the quantitative, qualitative and temporal alterations elicited by TAg, but also when coupled with analysis of regression, should distinguish between fixed and reversible aspects of the tumorigenic process.
